No black box warning on record for Cabergoline

As of the latest FDA labeling reviewed, Cabergoline (CABERGOLINE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Cabergoline medicine page for the complete safety profile.

Other warnings & precautions

WARNINGS 1. Pregnancy: Dopamine agonists in general should not be used in patients with pregnancy-induced hypertension, for example, preeclampsia, eclampsia, and postpartum hypertension, unless the potential benefit is judged to outweigh the possible risk. 2. Fibrotic Complications: a. Cardiac Valvulopathy: All patients should undergo a cardiovascular evaluation, including echocardiogram to assess

No black box warning on record for Cabergoline

Other warnings & precautions

WARNINGS 1. Pregnancy: Dopamine agonists in general should not be used in patients with pregnancy-induced hypertension, for example, preeclampsia, eclampsia, and postpartum hypertension, unless the potential benefit is judged to outweigh the possible risk. 2. Fibrotic Complications: a. Cardiac Valvulopathy: All patients should undergo a cardiovascular evaluation, including echocardiogram to assess

Cabergoline Black Box Warning

No black box warning on record for Cabergoline

Other warnings & precautions

Cabergoline Black Box Warning

No black box warning on record for Cabergoline

Other warnings & precautions